T he behavioral and psychological symptoms of dementia are found in patients with all types and stages of dementia and occur in clusters or syndromes such as psychosis (delusions and hallucinations), agitation, aggression, and disinhibition. [1] [2] [3] Nonpharmacologic interventions-better stated as behavioral and environmental interventions-are recommended by numerous guidelines, medical organizations, and expert groups as the preferred first-line treatment, [4] [5] [6] [7] although they have largely not been translated into routine clinical practice. 8 Despite the fact that no drugs have been approved by the US Food and Drug Administration (FDA) for the behavioral and psychological symptoms of dementia, the current mainstay of treatment is the off-label use of psychotropic medications. 9,10 Of such agents, atypical antipsychotics have the strongest base of evidence, although their benefits are moderate at best and they are associated with a significant increase in the risk of stroke and mortality. 11, 12 Given the concerns regarding mortality, the FDA issued black box warnings for atypical antipsychotics in 2005 and for conventional antipsychotics in 2008.
To address the continued high use of antipsychotics in patients in long-term care settings, the Centers for Medicare & Medicaid Services (CMS) launched the National Partnership to Improve Dementia Care in Nursing Homes (hereafter referred to as the partnership) in 2012 to "improve the quality of care" for nursing home residents with dementia. 13 Although CMS developed a training program to promote "personcentered…high quality care" and the use of nonpharmacologic treatment alternatives to antipsychotics, 13 the program's quality measure is the prevalence of antipsychotic use, which CMS began reporting publicly through the Nursing Home Compare website and the Five-Star Quality Rating System for nursing homes. 14 According to CMS, antipsychotic prescribing to patients in long-term care has decreased since the start of the partnership by more than 30%. 15 However, it is unclear to what extent the use of antipsychotics was already declining before initiation of the partnership and what its association has been with the use of other psychotropic medications. Prior work examining antipsychotic prescribing in a national health care system found that, while the use of antipsychotics declined after the 2005 FDA black box warning, the overall rate of psychotropic use was unchanged, but the one class for which prescribing increased was mood stabilizers. 16 These medications-primarily antiepileptic drugs, such as sodium valproate or carbamazepine-are typically used by psychiatrists to treat patients with bipolar disorder. Although reports of the use of benzodiazepines or mood stabilizers for the behavioral and psychological symptoms of dementia have been published for decades, there is no highquality evidence of efficacy for treating such symptoms of dementia with these alternatives to antipsychotics, while they are associated with a host of harms. 12,17-25 Despite limited evidence to justify their use, mood stabilizers feature on candidate lists aimed at clinicians of medications to address the behavioral and psychological symptoms of dementia.
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Although antidepressants may have efficacy for agitation, 29 they have not shown efficacy for depression in dementia in 5 randomized clinical trials, 30 and they, too, carry risk of a Medicare fee-for-service beneficiaries with any long-term care during study period.
b Determined based on health care encounters during the 12 months preceding entry into long-term care.
c Weighted score based on the presence of dementia, myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic obstructive pulmonary disease, rheumatologic disease, peptic ulcer disease, cirrhosis, hepatic failure (weighted by 3), diabetes mellitus, diabetes mellitus with complications (weighted by 2), hemiplegia (weighted by 2), chronic renal disease (weighted by 2), malignant neoplasm (weighted by 2), leukemia (weighted by 2), lymphomas (weighted by 2), metastatic solid tumor (weighted by 6), HIV without AIDS (weighted by 2), and AIDS (weighted by 6).
adverse events for frail older adults such as nausea, hyponatremia, and cardiac conduction abnormalities. A recent examination of nursing facility survey data at the facility level found a reduction in antipsychotic and psychotropic use overall after initiation of the partnership. 31 However, this analysis did not analyze prescribing trends leading to the partnership and, critically, did not include mood stabilizers. Although antipsychotic use has declined since initiation of the partnership, a concerning potential unintended consequence would be if clinicians have used medication substitution to a different but unmeasured psychotropic agent, such as a mood stabilizer. Such substitutes have even less evidence of benefit than antipsychotics yet similar potential for harms 20 and could suggest that increased use of nonpharmacologic treatments, which was a key goal of the partnership, 13 has not occurred.
Methods
To track antipsychotic use, the partnership uses the "Percent of Residents Who Received an Antipsychotic Medication (Long-Stay)" measure from the Minimum Data Set (MDS), version 3.0, 32 reported on a quarterly basis.
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Although it is the National Partnership to Improve Dementia Care, the quality measure that the partnership uses and reports is not limited to residents with dementia. Our study denominator and numerator were constructed to approximate this MDS measure. However, because improving dementia care is the stated intent, we conducted secondary analyses limited to the subgroup of patients with dementia. This study was approved by the University of Michigan Medical School institutional review board, which waived patient consent for these deidentified data.
Study Cohort
The data are drawn from a 20% sample of Medicare beneficiaries from January We grouped the data into sequential 3-month quarters and determined all prescriptions for a psychotropic medication of interest during a given quarter. Although 16 742 003 of 18 349 496 medication claims (91.2%) were for 30 days or less, we used the claim date and days' supply to attribute medication use to all possible quarters (eg, a 14-day prescription filled in the final week of 2013 quarter 1 contributed to the numerator for both quarters 1 and 2). This method allowed us to calculate the outcomes of interest-percentages of long-stay patients prescribed each medication class-on a quarterly basis. 
Statistical Analysis
Statistical analysis was conducted from May 1, 2017, to January 9, 2018. We used an interrupted time-series analysis to examine the association of the initiation of the partnership with prescribing of antipsychotics and other psychotropic medications. Period 1 is before initiation of the partnership (2009, quarter 1, through 2012, quarter 1) and period 2 is after initiation of the partnership (2012, quarter 2, through 2014, quarter 4). Our model used quarterly percentages as the dependent variable and included a linear time-trend variable, an indicator for the postpartnership time period to determine changes in the mean level of prescribing during each time period, and a term for the change in the linear time trend (slope) between periods 1 and 2. We used 2-tailed t tests to test the statistical significance of the partnership and controlled for autocorrelation by assuming a first-order autoregressive process. Because the partnership was launched specifically to improve care of patients with dementia, we repeated the analysis of medication use for the subcohort of patients with dementia. Owing to the large sample size, P < .01 was considered significant.
Results
Our final cohort included 637 426 patients with a long stay (≥100 days) in a nursing facility between 2009 and 2014 ( Psychotropic Prescribing Among Long-term Care Residents Overall Figure 1 presents the percentage of patients prescribed a psychotropic or memory medication on a quarterly basis before (period 1) and after (period 2) initiation of the partnership (eTable 3 in the Supplement presents the quarterly rates represented in Figure 1 ). At the start of 2009, a total of 31 056 of 145 841 patients (21.3%) were prescribed an antipsychotic medication; this rate fell during period 1 (ie, before the start of the partnership), with a mean decline of -0.53% per quarter (95% CI, -0.63% to -0.44%; P < .001) ( Table 2) . By the end of period 2 (2014, quarter 4), antipsychotic use had fallen further to 40 956 of 355 716 patients (11.5%) (eTable 3 in the Supplement), but the quarterly rate of decline slowed significantly from period 1 to 2 by 0.24% (95% CI, 0.09%-0.39%; P = .003). Among nonantipsychotic medications, mood stabilizers were the only medication class for which use increased. The quarterly rate of prescribing increased significantly during period 1 (0.07%; 95% CI, 0.05%-0.10%; P < .001), but the growth accelerated significantly after initiation of the partnership, with a quarterly rate increase that was 0.14% higher (95% CI, 0.10%-0.18%; P < .001) ( Table 2) . By the end of 2014, a total of 71 492 of 355 716 patients (20.1%) were prescribed a mood stabilizer (eTable 3 in the Supplement).
Antidepressants were the most commonly prescribed psychotropic medication at all time points, although prescribing declined across both study periods and, as with antipsy- chotic use, the rate of decline slowed from period 1 to period 2 by 0.34% (95% CI, 0.18%-0.50%; P < .001) ( Table 2) . Use of nonbenzodiazepine sedative-hypnotics was unchanged during period 1 but declined significantly during period 2 by -0.18% per quarter (95% CI, -0.20% to -0.16%; P < .001) ( Table 2) The use of nonantipsychotic psychotropic medication overall mirrored the changes in antipsychotic use, with decreasing use during the first period and slower but still declining use after initiation of the partnership (Table 2) . When including antipsychotics and benzodiazepines, 214 761 of 355 716 patients (60.4%) were prescribed a psychotropic by the end of 2014 (eTable 3 in the Supplement). Prescribing of memory medications was similar to prescribing of psychotropic medications overall, with declines across both periods.
To determine whether the increase in prescribing of mood stabilizers was associated with an increase in the prevalence of seizure disorders among the cohort, we assessed the quarterly prevalence of seizure disorders, which was stable during both period 1 (0.12% per quarter; 95% CI, -0.02% to 0.26%; P = .09) and period 2 (-0.03% per quarter; 95% CI, -0.20% to 0.15%; P = .08). In addition, we may have had incomplete capture of medication use for patients with hospitalization or hospice use during their observation period.
We completed 2 additional sensitivity analyses: one excluding patients with any inpatient use (eTable 4 in the Supplement) and one censoring observation 180 days before death (ie, as a proxy for eligibility for hospice) (eTable 5 in the Supplement). In both analyses, the significance of slope changes between periods for all medication groups was unchanged.
Psychotropic Prescribing Among Long-term Care Residents With Dementia
Among the subset of patients with dementia, the use of psychotropic medication was higher than among the overall study sample (Figure 2;eTable6intheSupplement) , but the overall trends in use across the study periods were similar ( Table 3) . The use of antipsychotics declined through periods 1 and 2 to 27 874 of 135 646 patients (20.5%) by the final quarter; the partnership appeared to have no association with the rate of this decline (slope change, -0.003%; 95% CI, -0.14% to 0.13%; P = .96). The use of antidepressants declined at a steady rate through both periods, with no difference after initiation of the partnership.
Prescribing of mood stabilizers increased during both periods, and prescribing increased more rapidly in period 2 (slope change, 0.14%; 95% CI, 0.10%-0.18%; P < .001) ( Table 3) 
Discussion
In this national Medicare sample of patients in long-term care, we found that antipsychotic use has declined since the initiation of the partnership, as previously reported.
14,15,31 However, the program does not appear to have accelerated the decline that was already occurring. What has not been previously reported, to our knowledge, is the growing use of mood stabilizers, which increased more quickly after the start of the partnership.
Although the increase in the use of mood stabilizers was relatively small-an absolute increase of 2.5% from the final quarter before initiation of the partnership to the end of 2014-it was the only medication class that did not experience a decline, and the increase mirrors growth in use of mood stabilizers that Kales et al 16 and their substitution for antipsychotics could be expected, analyses of psychotropic prescribing in nursing homes frequently do not include mood stabilizers. 31,37-39 The MDS, the federally mandated health assessment survey used for all nursing home residents and the source of data for the partnership antipsychotic measure, collects information on the use of several psychotropic classes, but information on mood stabilizers is not captured; thus, the most likely substitute for antipsychotics has gone unobserved.
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Behavioral and environmental strategies, despite the growing evidence base and greater efficacy than antipsychotics, [41] [42] [43] have not been routinely translated into long-term care settings. The key goal of the partnership is clearly to help correct this issue: through emphasizing reductions in antipsychotic prescribing by measuring and publicly reporting it, facilities might increase the use of evidence-based, nonpharmacologic alternatives. 13 However, what is being measured and reported is prescribing of antipsychotics. Without additional resources to implement behavioral and environmental strategies, clinicians may have chosen to shift patients to alternative psychotropic classes. In addition to the psychotropics measured in our study, an investigative report highlighted the recent, rapid growth in off-label prescribing of dextromethorphan hydrobromide-quinidine sulfate for agitation in patients with dementia. 44 The medication's manufacturer specifically targeted facilities with high rates of antipsychotic use who would see dextromethorphan-quinidine "as an attractive alternative," given the close monitoring of antipsychotic prescribing. As long as antipsychotic prescribing is the only quality measure, substitutions to bypass surveillance will continue. There are limited longitudinal data on psychotropic prescribing in long-term care with which to compare our analysis. The available evidence suggests that use of antipsychotics was already declining prior to initiation of the partnership, as we found. Chen et al, 45 using an analysis of US nursing home pharmacy dis- In the final quarter of 2014, more than 60% of long-term stay nursing home residents were prescribed a psychotropic medication. The persistently high use of benzodiazepines is particularly concerning given their association with several adverse events in older adults, including falls, 47 
Conclusions
Use of antipsychotic medications was declining before the start of the partnership and continued to fall after its start. At the same time, prescribing of mood stabilizers, an unmeasured alternative possibly prescribed for behavioral and psychological symptoms of dementia, has been growing. Initiatives focused on improving psychotropic prescribing for patients with dementia should monitor use of other psychotropicsincluding mood stabilizers-as well as consider how to measure and incentivize structured, evidence-based, nonpharmacologic alternatives. Given the barriers to increased uptake of behavioral and environmental interventions relative to simply shifting prescribing, such measurement is essential to further the primary goal of improving person-centered dementia care rather than simply encouraging a shift to prescribing alternative but unmeasured medications. n/a n/a n/a 18.9 0.05 (-0.04, 0.13) .206 n/a n/a n/a n/a n/a n/a 19.0 0.05 (-0.02, 0.12) .120 n/a n/a n/a Memory 28. 
